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Biosimilar G-CSFs are widely employed today for different clinical
indications including hematopoietic stem cell mobilization, despite lack
of robust evidence in this setting. Different single-institution
retrospective studies compared mobilization kinetics of patients given
biosimilar G-CSFs or originator compound, overall reporting equivalent
activity.1-3 However, extremely little evidence is available about
comparative efficacy of biosimilar and originator compounds when
G-CSF is combined with plerixafor to rescue patients at high risk of
mobilization failure.4
We herein report the results of a retrospective analysis of 296
patients affected by multiple myeloma (MM), non-Hodgkin (NHL), or
Hodgkin lymphoma (HL) who underwent PBSC mobilization with
G-CSF and plerixafor as part of the mobilizing strategy at 22 italian
centers from January 2008 to December 2016 (patient characteristics
are presented in Supporting Information Table 1). G-CSF compound
employed was either originator (Neupogen®, Amgen) or biosimilar
filgrastim (Zarzio®, Sandoz Industrial Products; Tevagrastim®, Teva
Pharmaceutical Industries). Originator or biosimilar filgrastim were
administered subcutaneously at a dosage of 5 lg/kg/day (following
chemotherapy) or 10 lg/kg/day (in case of steady-state mobilization).
Plerixafor was given at a dosage of 240 mcg/kg body weight. Periph-
eral blood CD341 (PB-CD341) were measured at hematopoietic
recovery (in case of chemo-mobilization) or at day 4 of G-CSF adminis-
tration (in case of steady-state mobilization), and then daily until stem
cell collection completion or failure. The threshold of PB-CD341 cells
for starting apheresis procedure was established at 20 3 106/L. Given
the retrospective nature of the study, a propensity score weighted
analysis was conducted in order to soften inherent limitations as
imbalances between the two study groups in terms of patient and
mobilization characteristics.5
A total of 296 patients were included in the analysis. Forty-two
percent of patients (n5123) were affected by MM, 49% (n5143) by
NHL and 9% (n529) by HL. Forty percent of patients (n5118) under-
went chemo-mobilization, while 60% (n5178) steady-state mobiliza-
tion. One hundred and ninety-seven patients (67%) received originator
filgrastim combined with plerixafor (OR1PLX), while 99 patients (33%)
were given biosimilar filgrastim and plerixafor (BIO1PLX). The median
PB-CD341 count before and after plerixafor administration were
8/mcl (IQR 3–12), and 33/mcl (IQR 15–58), respectively, with an
average 6-fold increase.
Patients included in the BIO1PLX cohort were more likely to
exceed the PB-CD341 threshold of 5/mcl before plerixafor
administration, as compared to the OR1PLX group, as evidenced by
propensity score weighted analysis (weighted OR53.6; robust 95% CI
1.5–8.4). Further, patients receiving BIO1PLX showed higher proba-
bility of reaching the PB-CD341 threshold of 20/mcl after plerixafor
administration, as compared to the OR-PLX group (weighted OR56.8;
robust 95% CI 2.6–17.6). Finally, patient mobilized with the BIO1PLX
combination were more likely to collecting a stem cell dose of 2 3 106
CD341/kg or higher (weighted OR56.1; robust 95% CI 1.9–18.9).
The combination of BIO1PLX appeared to be more efficient in
term of primary endpoints both in MM and lymphoma subgroups,
although confidence intervals resulted quite wide, probably due to
reduced sample size (Table T11). Patients who received BIO1PLX
were more likely to reach the apheresis procedure as compared to
OR1PLX group (weighted OR55.3; robust 95% CI 1.1–26.4)
without any difference in the number of apheresis procedures (one
or more) required to complete stem cell collection (weighted
OR50.7; robust 95% CI 0.3–1.5). One hundred and seventy-eight
patients (62%) received autologous transplant as planned, 79%
of the patients who collected at least 2 3 106 CD341/kg. The
mobilization strategy (BIO1PLX or OR1PLX) did not influence the
probability of performing the planned auto-SCT procedure
(weighted OR51.5; robust 95% CI 0.7–3.4). Engraftment was
successful in 97% of patients with no significant difference between
the two study cohorts.
In the largest study comparing two different biosimilar G-CSFs
and the originator drug in association with plerixafor, we observed a
powerful mobilizing efficacy of the combination of biosimilar filgras-
tim and plerixafor, which was not inferior and, surprisingly, even
more powerful as compared to the combination with originator
G-CSF. Interestingly, in our series, biosimilar filgrastim resulted
in higher probability of reaching the pre-plerixafor PB-CD341
threshold of 5/mcl as compared to originator G-CSF. Further,
BIO1PLX was associated with an increased likelihood to get to the
threshold of 20/mcl and, as a direct consequence, to collect at least
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2 3 106 CD341/kg, as compared to OR1PLX. Our analysis con-
firms previous evidence of noninferiority of biosimilar to originator
filgrastim,6 and suggests an even higher mobilizing power of
BIO1PLX as compared to OR1PLX. Considering the constant
improvement of pharmaceutical manufacturing techniques it might
come as no surprise that a newer drug which is required to be “at
least not inferior” actually turns out to be more efficient than the
older one. It should be noted, however, that patients given the
BIO1PLX combination underwent stem cell mobilization signifi-
cantly more recently as compared to OR1PLX group; this might
have somehow influenced data analysis, as it could be speculated
that advancements in recent years brought a significant improve-
ment in apheresis techniques, mobilization strategies and maybe
even plerixafor use.
In conclusion, the combination of biosimilar filgrastim and
plerixafor appears to be at least equally and might be more effective
as compared to originator filgrastim and plerixafor for stem cell
mobilization in patients at high risk of mobilization failure. This
data strongly support standard inclusion of biosimilar filgrastim in
mobilizing protocols even in the challenging setting of patients who
mobilize poorly, as significant cost saving seems to be accompanied
by strong efficacy.
TABLE 1 Efficacy of BIO1PLX as compared to OR1PLX on stem cell mobilization with regards to primary endpoints
Panel A: descriptive analysis
PB-CD341 count pre-plerixafor administration
PB-CD341 before PLX
Median (IQR)
PB-CD341 before PLX >5/mcl
% of patients
BIO1PLX cohort 10.0 (6.0–16.0) 77%
OR1PLX cohort 5.3 (2.0–9.0) 51%
PB-CD341 count after plerixafor administration
PB-CD341 after PLX
Median (IQR)
PB-CD341 after PLX >20/mcl
% of patients
BIO1PLX cohort 50.2 (30.0–71.0) 88%
OR1PLX cohort 24.0 (12.0–48.0) 56%
CD341/Kg body weight collected in up to 4 apheresis procedures
CD341/Kg collected
Median (IQR)
CD341/Kg collected >2 3 106
% of patients
BIO1PLX cohort 4.2 (3.0–5.9) 92%
OR1PLX cohort 4.0 (2.5–6.8) 82%
Panel B: propensity score weighted logistic regression analysis
Probability of exceeding the PB-CD341 threshold of 5/mcl (pre-plerixafor)
BIO1PLX cohort weighted OR robust 95% CI
Entire sample 3.6 1.5 8.4
Multiple myeloma patients 6.9 2.0 23.9
Lymphoma patients 2.4 0.8 7.0
Probability of exceeding the PB-CD341 threshold of 20/mcl (after plerixafor)
BIO1PLX cohort weighted OR robust 95% CI
Entire sample 6.8 2.6 17.6
Multiple Myeloma patients 4.3 1.3 14.4
Lymphoma patients 10.5 2.3 48.3
Probability of collecting at least 2 3 106 CD341/Kg
BIO1PLX cohort weighted OR robust 95% CI
Entire sample 6.1 1.9 18.9
Multiple myeloma patients 5.5 0.6 50.4
Lymphoma patients 6.9 1.8 26.5
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SUPPORTING INFORMATION
Additional Supporting Information may be found in the online
version of this article.
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